ポンチングリオーマ治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Pontine Glioma - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0548
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:438
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Pontine Glioma – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma – Pipeline Review, H2 2019, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.

Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 16, 12, 1, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 3, 1 and 1 molecules, respectively.

Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pontine Glioma – Overview
Pontine Glioma – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pontine Glioma – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pontine Glioma – Companies Involved in Therapeutics Development
Accendatech Au Pty Ltd
Adastra Pharmaceuticals Inc
Apexigen Inc
Bayer AG
Bexion Pharmaceuticals LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Burzynski Research Institute Inc
CDG Therapeutics Inc
Curis Inc
DelMar Pharmaceuticals Inc
DNAtrix Inc
Eli Lilly and Co
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd
Insys Therapeutics Inc
Kazia Therapeutics Ltd
M4K Pharma Inc
Mana Therapeutics Inc
Medicenna Therapeutics Corp
Midatech Pharma Plc
Moleculin Biotech LLC
NewLink Genetics Corp
Novartis AG
Noxopharm Ltd
Oncoceutics Inc
OncoRx Pharmaceuticals Inc
Oncotelic Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
Regeneron Pharmaceuticals Inc
Shionogi & Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Xcovery Holding Company LLC
Y-mAbs Therapeutics Inc
ZIOPHARM Oncology Inc
Pontine Glioma – Drug Profiles
Pontine Glioma – Dormant Projects
Pontine Glioma – Discontinued Products
Pontine Glioma – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Pontine Glioma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pontine Glioma - Pipeline by Accendatech Au Pty Ltd, H2 2019
Pontine Glioma - Pipeline by Adastra Pharmaceuticals Inc, H2 2019
Pontine Glioma - Pipeline by Apexigen Inc, H2 2019
Pontine Glioma - Pipeline by Bayer AG, H2 2019
Pontine Glioma - Pipeline by Bexion Pharmaceuticals LLC, H2 2019
Pontine Glioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pontine Glioma - Pipeline by Bristol-Myers Squibb Co, H2 2019
Pontine Glioma - Pipeline by Burzynski Research Institute Inc, H2 2019
Pontine Glioma - Pipeline by CDG Therapeutics Inc, H2 2019
Pontine Glioma - Pipeline by Curis Inc, H2 2019
Pontine Glioma - Pipeline by DelMar Pharmaceuticals Inc, H2 2019
Pontine Glioma - Pipeline by DNAtrix Inc, H2 2019
Pontine Glioma - Dormant Projects, H2 2019
Pontine Glioma - Discontinued Products, H2 2019

【掲載企業】

Accendatech Au Pty Ltd
Adastra Pharmaceuticals Inc
Apexigen Inc
Bayer AG
Bexion Pharmaceuticals LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Burzynski Research Institute Inc
CDG Therapeutics Inc
Curis Inc
DelMar Pharmaceuticals Inc
DNAtrix Inc
Eli Lilly and Co
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd
Insys Therapeutics Inc
Kazia Therapeutics Ltd
M4K Pharma Inc
Mana Therapeutics Inc
Medicenna Therapeutics Corp
Midatech Pharma Plc
Moleculin Biotech LLC
NewLink Genetics Corp
Novartis AG
Noxopharm Ltd
Oncoceutics Inc
OncoRx Pharmaceuticals Inc
Oncotelic Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
Regeneron Pharmaceuticals Inc
Shionogi & Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Xcovery Holding Company LLC
Y-mAbs Therapeutics Inc
ZIOPHARM Oncology Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ポンチングリオーマ治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆